Androgen receptor (AR) degradation enhancer ASC-J9® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth
Keywords: Androgen receptor; Prostate cancer; Prostate therapy; ASC-J9®; IC50; Epithelial cells; Stromal cells; Fibroblasts; Myofibroblasts; Apoptosis; FDA-approved formula; AR; androgen receptor; PCa; prostate cancer; RT-PCR; reverse transcription polymerase chai